Stock Market News
Broker snap: Shire rated 'buy', but Jefferies disappointed with Vyvanse trial
07-02-2014 09:45
Add To Google +1 | Tweet |
Jefferies has kept its 'buy' rating for pharmaceuticals group Shire saying that it still sees 'attractive growth', but was disappointed by the outcome of clinical trials for the company's major depressive disorder (MDD) treatment, Vyvanse.
Shire said on Friday that it will no longer pursue the development of Vyvanse after top-line results from two pivotal Phase 3 investigational studies evaluating the efficacy and safety of the drug showed it failed to meet objectives.
The company will later in the year file with the US Food and Drug Administration for a new indication for Vyvanse in binge eating disorder (BED) in adults.
"We were more optimistic for expanded use of Vyvanse in MDD than BED, so the setback comes as a negative surprise," said Jefferies analysts Peter Welford and Chris Cooper.
They estimated that Vyvanse in MDD had a 85p-a-share net present value in their sum-of-the-parts valuation, and had forecast a $350m contribution to revenues in 2018, equivalent to 4% of group sales.
"Pipeline focus is now increasingly on rare orphan diseases, potentially putting pressure on management to execute more business development deals and/or M&A, in our view, with ophthalmology and blood cancers possible targets," the broker said.
"We would use likely share price weakness today as a buying opportunity given at least c14% forecast earnings per share compound annual growth rate over 2014-17 and a price-to-earnings ratio of 14 (on 2015 estimates)."
The stock was 0.7% lower at 3,118p by 10:00 on Friday.
BC
Shire said on Friday that it will no longer pursue the development of Vyvanse after top-line results from two pivotal Phase 3 investigational studies evaluating the efficacy and safety of the drug showed it failed to meet objectives.
The company will later in the year file with the US Food and Drug Administration for a new indication for Vyvanse in binge eating disorder (BED) in adults.
"We were more optimistic for expanded use of Vyvanse in MDD than BED, so the setback comes as a negative surprise," said Jefferies analysts Peter Welford and Chris Cooper.
They estimated that Vyvanse in MDD had a 85p-a-share net present value in their sum-of-the-parts valuation, and had forecast a $350m contribution to revenues in 2018, equivalent to 4% of group sales.
"Pipeline focus is now increasingly on rare orphan diseases, potentially putting pressure on management to execute more business development deals and/or M&A, in our view, with ophthalmology and blood cancers possible targets," the broker said.
"We would use likely share price weakness today as a buying opportunity given at least c14% forecast earnings per share compound annual growth rate over 2014-17 and a price-to-earnings ratio of 14 (on 2015 estimates)."
The stock was 0.7% lower at 3,118p by 10:00 on Friday.
BC
Related share prices |
---|
Shire Plc (SHP) share price |
Stock News is provided by Digital Look Corporate Solutions from Sharecast news. Please read the terms and conditions of useage of this data. Republication or redistribution of content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd.
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- RBS share price
- Diageo share price
- Standard Life Share Price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- Morrisons Share Price
- Aviva Share Price
- LGO Share price
- Tullow Oil Share Price
- SXX Share Price
- Easyjet Share Price
- Next Share Price
- Thomas Cook Share Price
- SSE Share Price
- IAG Share Price
- Bat share price
- Monitise Share Price
- Kingfisher share price
- Dragon Oil share price
- UKOG share price
- SOLG share price